Abstract
Objective: We aimed to prospectively evaluate the effects of pegylated interferon alpha-2a and alpha-2b therapy on chromosomal aberrations and mitotic index in patients with chronic hepatitis B. Material and Methods: Fifty patients with chronic hepatitis B who underwent pegylated interferon alpha-2a or 2b therapy were evaluated for chromosomal aberrations and mitotic index before the treatment and at the end of 6 months of therapy. Results: Cytogenetic examinations revealed out that there was no significant difference between pre- and post-treatment frequencies of mitotic index and chromosomal aberrations. Conclusion: Interferon alpha-2a and alpha-2b therapy which is associated with common hematologic adverse effects has no significant cytogenetic effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
